A Phase 1a Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI9314 in Healthy Adult Subjects

Trial Profile

A Phase 1a Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI9314 in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs MEDI 9314 (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions
  • Sponsors MedImmune
  • Most Recent Events

    • 11 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 21 Nov 2016 Status changed from recruiting to active, no longer recruiting.
    • 15 Sep 2016 Planned End Date changed from 1 May 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top